MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Critical Care
Critical Care

Biomarker Signatures in Sepsis: Linking Host Response to Clinical Outcomes

MedXY Editorial TeamApr 27, 2026
biomarkersdisease tolerancehost resistancesepsis

Highlights

1. Biomarker signatures for host resistance, disease tolerance, and damage were analyzed in sepsis patients.

2. Greater host damage was significantly associated with increased 90-day mortality.

3. Sepsis subtypes showed distinct patterns in disease tolerance and damage signatures.

Background

Sepsis remains a leading cause of mortality worldwide, with complex pathophysiology involving host resistance to infection, disease tolerance, and host damage. Despite advances in understanding, biomarkers that reliably predict outcomes and subtype classifications are needed to guide personalized treatment strategies.

Study Design

The study prospectively enrolled 444 adults meeting Sepsis-3 criteria within 6 hours of emergency department arrival. Participants were assigned clinical subtypes (α, β, γ, δ) using the Sepsis ENdotyping in Emergency CAre (SENECA) approach. Sixteen plasma and urinary biomarkers were grouped into three mechanistic axes: host resistance, disease tolerance, and damage. Principal component analysis and multivariable logistic regression were used to assess associations with 90-day mortality and sepsis subtype membership.

Key Findings

The mean age of participants was 60 years, with a mean SOFA score of 4.3 and a 90-day mortality rate of 17%. Greater host damage was significantly associated with increased mortality (aOR = 1.70; 95% CI 1.38-2.11; p < 0.001), while host resistance and disease tolerance showed no significant association. Sepsis subtypes exhibited distinct biomarker profiles, with δ-type patients showing higher damage and lower disease tolerance, and α-type patients showing the opposite pattern.

Expert Commentary

This study provides valuable insights into the mechanistic underpinnings of sepsis, highlighting the role of host damage in mortality. The findings suggest that biomarker signatures could enhance subtype classification and prognostication, though further validation is needed. Limitations include the single-center design and reliance on remnant biospecimens.

Conclusion

Biomarker signatures aligned with host resistance, disease tolerance, and damage offer a novel approach to understanding sepsis pathophysiology and outcomes. These findings may inform future research and therapeutic strategies, addressing unmet needs in sepsis management.

Funding and ClinicalTrials.gov

The study was supported by institutional funding. ClinicalTrials.gov registration was not provided.

References

Chowdhury A, et al. Intensive Care Medicine. 2026.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Mitochondrial Dysfunction and Platelet Hyperactivation: A Novel Therapeutic Target in Sepsis

Critical CareNov 3, 2026

Shorter Is Often Better: Expert Consensus on Antibiotic Duration in Sepsis and Severe Infections in the ICU

Critical CareOct 22, 2026

Analyzing Variability in Pediatric ECPR Survival After In-Hospital Cardiac Arrest: Development and Validation of a Risk-Standardized Survival Model

Critical CareNov 5, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story